Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
|
SAN FRANCISCO, Nov. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The call will be hosted by Nektar management and will also include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center. The event will follow Dr. Diab's oral presentation on Saturday evening of clinical data from a cohort of first-line Stage IV metastatic melanoma patients in the PIVOT-02 study of NKTR-214 in combination with nivolumab. Analyst Call with Melanoma Specialist Date: Sunday, November 10th at 9:00 a.m. Eastern Standard Time Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 9059428) Investors and analysts can also view slides and listen to the live audio webcast of the presentation at https://edge.media-server.com/mmc/p/jirxdbd4. The event will also be available for replay for two weeks on the company's website, www.nektar.com. Details of the oral presentation at SITC are as follows: Oral Presentation at SITC Date: Saturday, November 9th from 5:15 p.m. - 5:30 p.m. Eastern Standard Time Session Title: Concurrent Session 310: Combination Phase 1-2 Clinical Trials Abstract Title: "Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study" Abstract: O35 Presenter: Dr. Adi Diab, MD Anderson Cancer Center Details of the poster presentations are as follows: Additional Presentations at SITC Abstract P619: "NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models", Kivimäe, S., et al. Session Date and Time: Friday, November 8th from 7:00 a.m. - 8:00 p.m. Eastern Standard Time Abstract P623: "Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity", Pieper, A., et al. Session Date and Time: Friday, November 8th from 7:00 a.m. - 8:00 p.m. Eastern Standard Time Abstract P622: "Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist", Miyazaki, T., et al. Session Date and Time: Saturday, November 9th from 7:00 a.m. - 8:00 p.m. Eastern Standard Time Details of the Trials in Progress poster presentation are as follows: Trials in Progress Poster Presentation at SITC Abstract P387: "A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer (PORTER)", Nissola, L., et al. Session Date and Time: Friday, November 8th from 7:00 a.m. - 8:00 p.m. Eastern Standard Time About Nektar Contact: For Investors: For Media: Dan Budwick of 1AB SOURCE Nektar Therapeutics |
||
Company Codes: NASDAQ-NMS:NKTR |
View original content:
